Analysts Viewpoint PHAT stock price expected to increase by 18 in 12 months Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Phathom Pharmaceuticals
Analysts Viewpoint PHAT stock rated an Overweight by Cantor Fitzgerald Phathom Pharmaceuticals Inc’s filing revealed that its Principal Accounting Officer Breedlove Robert Charles unloaded Company’s shares for reported $14152.0 on
Insiders Updates Analysts: PHAT stock price target of 18 in 12 months Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Phathom Pharmaceuticals